Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34504347.
- Also identified by DOI 10.1038/s41587-021-00993-6 and PMC identifier 8532138.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The lack of samples for generating standardized DNA datasets for setting up a sequencing pipeline or benchmarking the performance of different algorithms limits the implementation and uptake of cancer genomics. Here, we describe reference call sets obtained from paired tumor-normal genomic DNA (gDNA) samples derived from a breast cancer cell line-which is highly heterogeneous, with an aneuploid genome, and enriched in somatic alterations-and a matched lymphoblastoid cell line. We partially validated both somatic mutations and germline variants in these call sets via whole-exome sequencing (WES) with different sequencing platforms and targeted sequencing with >2,000-fold coverage, spanning 82% of genomic regions with high confidence. Although the gDNA reference samples are not representative of primary cancer cells from a clinical sample, when setting up a sequencing pipeline, they not only minimize potential biases from technologies, assays and informatics but also provide a unique resource for benchmarking 'tumor-only' or 'matched tumor-normal' analyses.
Medical subject headings
- Benchmarking
- Breast Neoplasms
- DNA Mutational Analysis
- High-Throughput Nucleotide Sequencing
- Whole Genome Sequencing